WaveMan
WaveMan · Company
JUSH · Jushi Holdings Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

JUSH Jushi (JUSH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001909747
Quote by TradingView
Cluster · 4 insidersC-suite buying · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about JUSH

Insiders, 180 days
+$1.1M net bought
4 buyers

Jushi insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Jushi Holdings Inc. insiders bought a net $1.1M of stock across 24 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Cacioppo James
Chief Executive Officer
BUY
2026-09-22 SECtraded 2026-09-18
20
$10
-21.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Sep 1, 2026.
  • The trade is 0.0% of the 4,723,168 shares held after it.
  • 2 other insiders bought within 30 days.
Insider activity: Chief Executive Officer Cacioppo James bought about $10 of JUSH on Sep 18, 2026; 2 other insiders bought within 30 days.
Arsenault Denis J.
BUY
2026-09-14 SECtraded 2026-09-08
15,100
$9.4K
-18.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 3, 2026.
  • The trade is 0.2% of the 7,811,033 shares held after it.
  • 2 other insiders bought within 30 days.
Insider activity: Insider Arsenault Denis J. bought about $9.4K of JUSH on Sep 8, 2026; 2 other insiders bought within 30 days.
Arsenault Denis J.
BUY
2026-09-14 SECtraded 2026-09-03
118,034
$69.6K
-18.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.5% of the 7,795,933 shares held after it.
  • 2 other insiders bought within 30 days.
Insider activity: Insider Arsenault Denis J. bought about $69.6K of JUSH on Sep 3, 2026; 2 other insiders bought within 30 days.
Cacioppo James
Chief Executive Officer
BUY
2026-09-02 SECtraded 2026-09-01
248,000
$128.7K
-16.0%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Aug 31, 2026.
  • The trade is 5.3% of the 4,723,148 shares held after it.
  • 2 other insiders bought within 30 days.
Insider activity: Chief Executive Officer Cacioppo James bought about $128.7K of JUSH on Sep 1, 2026; 2 other insiders bought within 30 days.
Cacioppo James
Chief Executive Officer
BUY
2026-09-02 SECtraded 2026-08-31
71,686
$36.6K
-16.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Aug 27, 2026.
  • The trade is 1.6% of the 4,475,148 shares held after it.
  • 2 other insiders bought within 30 days.
Insider activity: Chief Executive Officer Cacioppo James bought about $36.6K of JUSH on Aug 31, 2026; 2 other insiders bought within 30 days.
24 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 19 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.1M over 180 days
+$1.1M over 90 days · +$1.1M of it by a 10%+ holder
more than 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+9.6% year over year (latest quarter)
more than 59% of Pharma & Biotech
Margin
-10.3% net margin (latest quarter)
more than 64% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.4% of the float short (float per yahoo 2026-10-26) · 1.3 days to cover · settled 2026-09-30
below 82% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch JUSH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-29.6%12M
-51%-28%-5%+18%2025-102025-122026-022026-042026-062026-082026-10 2026-08-26 · Cacioppo James bought $247.0K2026-08-27 · Cacioppo James bought $245.0K2026-08-24 · Cacioppo James bought $184.4K2026-08-25 · Cacioppo James bought $157.8K2026-09-01 · Cacioppo James bought $128.7K2026-09-03 · Arsenault Denis J. bought $69.6K2026-08-31 · Cacioppo James bought $36.6K2026-08-27 · Barack Louis Jon bought $15.0K2026-06-15 · MOSIER MICHELLE O bought $10.8K2026-09-08 · Arsenault Denis J. bought $9.4K2026-07-30 · Barack Louis Jon bought $7.8K2026-08-31 · Barack Louis Jon bought $7.8K2026-08-03 · Barack Louis Jon bought $4.4K2026-08-04 · Barack Louis Jon bought $4.3K2026-07-30 · Barack Louis Jon bought $4.0K2026-07-31 · Barack Louis Jon bought $2.7K2026-07-30 · Barack Louis Jon bought $2.3K2026-06-12 · MOSIER MICHELLE O bought $1.2K2026-06-12 · MOSIER MICHELLE O bought $4902026-09-18 · Cacioppo James bought $10
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns JUSH: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in JUSH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

JUSH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $1.1M bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

JUSH financials

Revenue growth
+9.6%
XBRL, annual
Net margin
-10.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$296.5M
market value at close 2026-10-26 on 2026-07-21 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

JUSH Stock Sonar score 4/7 axes

Find similar shapesCompare

JUSH ranks highest on insider conviction (91st percentile) and risk and compliance (87th), and lowest on institutional and government (37th), among Pharma & Biotech peers.

Growth
59
Inputs
  • Revenue growth, YoY+9.6% · 59 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
91
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.1M · 89 pct, sector of 428
  • Insider buyers, 180d4 · 94 pct, sector of 437
Institutional and government
37
Inputs
  • Funds adding, latest quarterfewer than five funds report holding it
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$180K · 37 pct, sector of 133
Risk and compliance
87
Inputs
  • Short interest, % of float+0.4% · 87 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+4.1% · 87 pct, sector of 511
3 not measured: Profitability, Financial health, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; needs four quarters of operating cash flow
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

JUSH filings, in plain words

Are Jushi insiders buying or selling JUSH?

In the 180 days to 2026-10-27, Jushi insiders were net buyers, a net $1.1M across purchases and sales reported on Form 4, by 4 buyers.

Read the full summary

In the 180 days to 2026-10-27, Jushi insiders were net buyers of JUSH, a net $1.1M across purchases and sales reported on Form 4 by 4 buyers. Most of that figure, $1.1M, came from a holder of 10% or more rather than an officer or director. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies